What is Zacks Research’s Estimate for Sanofi Q2 Earnings?

Sanofi (NASDAQ:SNY) – Research analysts at Zacks Research reduced their Q2 2025 EPS estimates for Sanofi in a research note issued to investors on Wednesday, March 5th. Zacks Research analyst K. Shah now forecasts that the company will earn $0.92 per share for the quarter, down from their previous estimate of $0.93. The consensus estimate for Sanofi’s current full-year earnings is $4.36 per share. Zacks Research also issued estimates for Sanofi’s Q4 2025 earnings at $0.80 EPS, FY2025 earnings at $4.14 EPS, Q1 2026 earnings at $1.00 EPS, Q3 2026 earnings at $1.36 EPS, Q4 2026 earnings at $1.10 EPS and FY2026 earnings at $4.46 EPS.

Sanofi (NASDAQ:SNY) last posted its quarterly earnings results on Thursday, January 30th. The company reported $0.70 earnings per share (EPS) for the quarter, meeting the consensus estimate of $0.70. Sanofi had a net margin of 12.77% and a return on equity of 25.61%.

SNY has been the topic of a number of other reports. Deutsche Bank Aktiengesellschaft raised shares of Sanofi from a “sell” rating to a “hold” rating in a report on Thursday, January 30th. Sanford C. Bernstein raised shares of Sanofi to a “strong-buy” rating in a report on Thursday, January 30th. Finally, StockNews.com cut shares of Sanofi from a “buy” rating to a “hold” rating in a report on Thursday, December 12th. Two analysts have rated the stock with a hold rating, one has given a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, the company has a consensus rating of “Buy” and a consensus target price of $60.00.

Sanofi Stock Down 0.3 %

Shares of NASDAQ:SNY opened at $59.25 on Friday. The stock has a market capitalization of $150.37 billion, a price-to-earnings ratio of 23.80, a price-to-earnings-growth ratio of 1.01 and a beta of 0.58. Sanofi has a 1-year low of $45.22 and a 1-year high of $59.72. The company’s fifty day moving average is $52.44 and its two-hundred day moving average is $52.73. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Institutional Trading of Sanofi

Hedge funds have recently made changes to their positions in the stock. Synergy Asset Management LLC bought a new position in Sanofi during the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. grew its holdings in Sanofi by 952.6% during the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company’s stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Lee Danner & Bass Inc. acquired a new position in Sanofi during the fourth quarter valued at approximately $31,000. Bessemer Group Inc. grew its holdings in Sanofi by 59.8% during the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company’s stock valued at $32,000 after purchasing an additional 242 shares during the last quarter. Finally, Sunbelt Securities Inc. grew its holdings in Sanofi by 72.1% during the third quarter. Sunbelt Securities Inc. now owns 747 shares of the company’s stock valued at $43,000 after purchasing an additional 313 shares during the last quarter. 14.04% of the stock is owned by hedge funds and other institutional investors.

Sanofi Company Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.